PPARGC1A and neoplasm: Conversely, co-cultivation of CD8+ T cells with PGC1α knockdown HT29 cells resulted in a significant reduction in both the anti-tumor ability of CD8+ T cells and the sensitivity of CRC cells to immunotherapy (Fig. 5K, L).